000285669 001__ 285669
000285669 005__ 20240229155115.0
000285669 0247_ $$2doi$$a10.3390/ijms242216386
000285669 0247_ $$2pmid$$apmid:38003576
000285669 0247_ $$2pmc$$apmc:PMC10671831
000285669 0247_ $$2ISSN$$a1422-0067
000285669 0247_ $$2ISSN$$a1661-6596
000285669 0247_ $$2altmetric$$aaltmetric:156903425
000285669 037__ $$aDKFZ-2023-02492
000285669 041__ $$aEnglish
000285669 082__ $$a540
000285669 1001_ $$aSteen, Sonja$$b0
000285669 245__ $$aDynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma.
000285669 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
000285669 3367_ $$2DRIVER$$aarticle
000285669 3367_ $$2DataCite$$aOutput Types/Journal article
000285669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701181702_17547
000285669 3367_ $$2BibTeX$$aARTICLE
000285669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285669 3367_ $$00$$2EndNote$$aJournal Article
000285669 520__ $$aThe introduction of immune checkpoint inhibition for recurrent and metastatic head and neck cancer has brought a new treatment option for patients suffering from advanced oral cancers without a chance for curation using surgery or radiotherapy. The application of immune checkpoint inhibitors in most cases is based on the expression levels of PD-L1 in the tumor tissue. To date, there is a lack of data on the dynamic regulation of PD-L1 during disease progression. Therefore, this study aimed to evaluate the expression levels of PD-L1 in a large cohort of patients (n = 222) with oral squamous cell carcinoma including primary and recurrent tumors. Semiautomatic digital pathology scoring was used for the assessment of PD-L1 expression levels in primary and recurrent oral squamous cell carcinoma. Survival analysis was performed to evaluate the prognostic significance of the protein expression at different stages of the disease. We found a significant up-regulation of PD-L1 expression from primary disease to recurrent tumors (mean PD-L1 H-scores: primary tumors: 47.1 ± 31.4; recurrent tumors: 103.5 ± 62.8, p < 0.001). In several cases, a shift from low PD-L1 expression in primary tumors to high PD-L1 expression in recurrent tumors was identified. Multivariate Cox regression analysis did not reveal a significantly higher risk of death (p = 0.078) or recurrence (p = 0.926) in patients with higher PD-L1 expression. Our findings indicate that the exclusive analysis of primary tumor tissue prior to the application of checkpoint blockade may lead to the misjudgment of PD-L1 expression in recurrent tumors.
000285669 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000285669 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285669 650_7 $$2Other$$aHNSCC
000285669 650_7 $$2Other$$aPD-L1
000285669 650_7 $$2Other$$aimmune checkpoint inhibitor
000285669 650_7 $$2Other$$ametastases
000285669 650_7 $$2Other$$aoral cancer
000285669 650_7 $$2Other$$arecurrence
000285669 650_7 $$2NLM Chemicals$$aB7-H1 Antigen
000285669 650_2 $$2MeSH$$aHumans
000285669 650_2 $$2MeSH$$aSquamous Cell Carcinoma of Head and Neck
000285669 650_2 $$2MeSH$$aCarcinoma, Squamous Cell: pathology
000285669 650_2 $$2MeSH$$aB7-H1 Antigen: metabolism
000285669 650_2 $$2MeSH$$aUp-Regulation
000285669 650_2 $$2MeSH$$aMouth Neoplasms: genetics
000285669 650_2 $$2MeSH$$aNeoplasm Recurrence, Local: genetics
000285669 650_2 $$2MeSH$$aHead and Neck Neoplasms
000285669 7001_ $$00000-0002-5187-1362$$aSemmelmayer, Karl$$b1
000285669 7001_ $$aFlechtenmacher, Christa$$b2
000285669 7001_ $$00000-0002-1322-755X$$aHoffmann, Jürgen$$b3
000285669 7001_ $$aFreier, Kolja$$b4
000285669 7001_ $$aHorn, Dominik$$b5
000285669 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b6$$udkfz
000285669 7001_ $$aFreudlsperger, Christian$$b7
000285669 7001_ $$00000-0002-0278-7228$$aMoratin, Julius$$b8
000285669 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms242216386$$gVol. 24, no. 22, p. 16386 -$$n22$$p16386$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
000285669 909CO $$ooai:inrepo02.dkfz.de:285669$$pVDB
000285669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000285669 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000285669 9141_ $$y2023
000285669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000285669 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000285669 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000285669 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-07T16:31:47Z
000285669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000285669 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000285669 9201_ $$0I:(DE-He78)E221-20160331$$kE221$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000285669 980__ $$ajournal
000285669 980__ $$aVDB
000285669 980__ $$aI:(DE-He78)E221-20160331
000285669 980__ $$aUNRESTRICTED